320 related articles for article (PubMed ID: 16886663)
1. Vitamin D compounds: clinical development as cancer therapy and prevention agents.
Trump DL; Muindi J; Fakih M; Yu WD; Johnson CS
Anticancer Res; 2006; 26(4A):2551-6. PubMed ID: 16886663
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor activity of calcitriol: pre-clinical and clinical studies.
Trump DL; Hershberger PA; Bernardi RJ; Ahmed S; Muindi J; Fakih M; Yu WD; Johnson CS
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):519-26. PubMed ID: 15225831
[TBL] [Abstract][Full Text] [Related]
3. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy.
Smith DC; Johnson CS; Freeman CC; Muindi J; Wilson JW; Trump DL
Clin Cancer Res; 1999 Jun; 5(6):1339-45. PubMed ID: 10389917
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer.
Trump DL; Potter DM; Muindi J; Brufsky A; Johnson CS
Cancer; 2006 May; 106(10):2136-42. PubMed ID: 16598750
[TBL] [Abstract][Full Text] [Related]
5. Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model.
Ahmed S; Johnson CS; Rueger RM; Trump DL
J Urol; 2002 Aug; 168(2):756-61. PubMed ID: 12131364
[TBL] [Abstract][Full Text] [Related]
6. Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role?
Porojnicu AC; Robsahm TE; Dahlback A; Berg JP; Christiani D; Bruland OS; Moan J
Lung Cancer; 2007 Mar; 55(3):263-70. PubMed ID: 17207891
[TBL] [Abstract][Full Text] [Related]
7. The antitumor efficacy of calcitriol: preclinical studies.
Johnson CS; Muindi JR; Hershberger PA; Trump DL
Anticancer Res; 2006; 26(4A):2543-9. PubMed ID: 16886662
[TBL] [Abstract][Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
9. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo.
Konety BR; Lavelle JP; Pirtskalaishvili G; Dhir R; Meyers SA; Nguyen TS; Hershberger P; Shurin MR; Johnson CS; Trump DL; Zeidel ML; Getzenberg RH
J Urol; 2001 Jan; 165(1):253-8. PubMed ID: 11125420
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D-related therapies in prostate cancer.
Johnson CS; Hershberger PA; Trump DL
Cancer Metastasis Rev; 2002; 21(2):147-58. PubMed ID: 12465754
[TBL] [Abstract][Full Text] [Related]
11. RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects.
Yin Y; Ni J; Chen M; Guo Y; Yeh S
Clin Cancer Res; 2009 Jan; 15(1):190-200. PubMed ID: 19118046
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells.
Alagbala AA; Johnson CS; Trump DL; Posner GH; Foster BA
Oncology; 2006; 70(6):483-92. PubMed ID: 17237623
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system.
Light BW; Yu WD; McElwain MC; Russell DM; Trump DL; Johnson CS
Cancer Res; 1997 Sep; 57(17):3759-64. PubMed ID: 9288784
[TBL] [Abstract][Full Text] [Related]
14. Calcitriol in the treatment of prostate cancer.
Beer TM; Myrthue A
Anticancer Res; 2006; 26(4A):2647-51. PubMed ID: 16886675
[TBL] [Abstract][Full Text] [Related]
15. The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice.
Wietrzyk J; Nevozhay D; Filip B; Milczarek M; Kutner A
Anticancer Res; 2007; 27(5A):3387-98. PubMed ID: 17970085
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.
Getzenberg RH; Light BW; Lapco PE; Konety BR; Nangia AK; Acierno JS; Dhir R; Shurin Z; Day RS; Trump DL; Johnson CS
Urology; 1997 Dec; 50(6):999-1006. PubMed ID: 9426741
[TBL] [Abstract][Full Text] [Related]
17. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs.
Schwartz GG; Oeler TA; Uskoković MR; Bahnson RR
Anticancer Res; 1994; 14(3A):1077-81. PubMed ID: 8074453
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy.
Trump DL; Deeb KK; Johnson CS
Cancer J; 2010; 16(1):1-9. PubMed ID: 20164683
[TBL] [Abstract][Full Text] [Related]
19. Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 pathways in 1,25D3-mediated apoptosis in squamous cell carcinoma cells.
Ma Y; Yu WD; Kong RX; Trump DL; Johnson CS
Cancer Res; 2006 Aug; 66(16):8131-8. PubMed ID: 16912191
[TBL] [Abstract][Full Text] [Related]
20. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
Morris MJ; Smaletz O; Solit D; Kelly WK; Slovin S; Flombaum C; Curley T; Delacruz A; Schwartz L; Fleisher M; Zhu A; Diani M; Fallon M; Scher HI
Cancer; 2004 May; 100(9):1868-75. PubMed ID: 15112267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
